WVE News and Press, Wave Life Sciences Ltd. From 03/04/21

Strong execution in 2020 sets stage for advancing five clinical programs and novel ADAR editing modality in 2021 Data from ongoing PRECISION-HD and OLE clinical trials for Huntington’s disease on track for end of 1Q 2021 Moving towards first patient dosing in thre...

CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and c...

Today, we take our first in-depth look at small biotech concern called Wave Life Sciences. Ironically, given its name, the shares go for just over $10 a piece. The company has multiple shots on goal and a partnership with Takeda to develop candidates in the CNS space. A full analy...

CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Exec...

Three clinical trials to begin in 2021 with compounds containing Wave’s novel PN backbone chemistry modifications Data from ongoing PRECISION-HD and OLE clinical trials for Huntington’s disease expected by end of 1Q 2021 Potential best-in-class ADAR editing...

CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Jonathan Rosin has been appointed as Chief Hu...

The following slide deck was published by Wave Life Sciences Ltd. in conjunction with their 2020 Q3 earnings call. For further details see: Wave Life Sciences Ltd. 2020 Q3 - Results - Earnings Call Presentation

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Exec...

Image source: The Motley Fool. WAVE Life Sciences Pte. Ltd. (NASDAQ: WVE) Q3 2020 Earnings Call Nov 9, 2020 , 8:30 a.m. ET Operator Continue reading For further details see: WAVE Life Sciences Pte. Ltd. (WVE) Q3 2020 Earnings Call Transcr...

Wave Life Sciences Ltd. (WVE) Q3 2020 Earnings Conference Call November 9, 2020 8:30 a.m. ET Company Participants Graham Morrell - IR Paul Bolno - President and CEO Mike Panzara - Chief Medical Officer, Head of Therapeutics Discovery and Development Dave Gaiero - Interim CFO Chandra Vargeese ...